Vaxart, Inc.: Appoints Raquel C. Bono to board

What happened

• Vaxart, Inc. announced on Oct 16, 2026 that its board appointed Raquel C. Bono, M.D., M.B.A., FACS, to serve on the board, effective immediately and until her successor is elected and qualified, or sooner in the event of her death, resignation, or removal. The board determined that Dr. Bono meets the independence standards adopted by the board.
• The company disclosed on Oct 19, 2026 that it issued a press release announcing the appointment.

Key details

• Dr. Bono will receive cash and equity compensation in the standard amounts previously approved by the board and as set forth in the Vaxart, Inc. Non-Employee Director Compensation Program.
• Dr. Bono entered into the company’s standard form of indemnification agreement (the form filed as Exhibit 10.3 to Vaxart’s Feb 20, 2018 Form 8-K).
• Dr. Bono has served as Principal of RCB Consulting, LLC since Oct 2019; served as CEO and chief of surgical innovation of Medical iSight from Apr 2024 to May 2026; served as Director of Washington State’s COVID-19 Health System Response Management from Mar 2020 to May 2023; served as chief health officer of Viking Cruises from Nov 2020 to Dec 2023; and retired from the U.S. Navy as a Vice Admiral in 2019 after more than 30 years, during which she served as Director of the Defense Health Agency, leading a joint agency responsible for a $50,000,000,000 worldwide health care enterprise.
• The filing states there are no arrangements or understandings between Dr. Bono and any other persons regarding her appointment, no family relationships with the company’s directors or executive officers, and no transactions requiring disclosure under Item 404(a) of Regulation S-K.

Why it may matter

• This Form 8-K reports Item 5.02 (departure of directors or certain officers; election of directors) and Item 7.01 (Regulation FD disclosure, press release). A filing does not show why the insider traded or why the company acted.